Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPRG4 in ocular graft-versus-host disease
NCT06495307Phase 2Terminated
- Sponsor
- Lubris BioPharma
- Start
- Feb 2025
- Primary completion
- Mar 2025
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human proteoglycan 4 in dry eye disease (DED), sponsored by Lubris BioPharma. Started Feb 2025; status: terminated.
02
Drugs
recombinant human proteoglycan 4
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT06495307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06495307.